Strong organic growth shadowed by Raipur losses and a missed breakeven
Reported PAT jumped 45%, but ₹9 crore in Raipur losses masks the real story: organic momentum is intact, yet guidance on profitability was revised downward by two quarters. EBITDA margin hit, but execution risk is rising.
The quarter at a glance
₹15.4 Cr
+45.2% YoY
~₹24 Cr
+60% YoY underlying
21.5%
+150 bps; target 21% hit
50.3%
+290 bps YoY
GPT Healthcare delivered headline PAT growth of 45%, but that number conceals two realities: organic profitability — revenue up 14%, mature hospitals ex-Raipur growing faster — is robust, while losses from the Raipur expansion ($9 crore in Q2 alone) drag consolidated earnings. Strip out Raipur, and underlying PAT growth approaches 60%. The tension is whether management can sustain organic momentum while absorbing mounting losses from two new hospitals (Raipur, Jamshedpur) and deliver on near-term profitability.
Where the profit came from — and what it costs
H1 FY27 revenue reached ₹261.8 Cr, up 15.8% YoY, tracking the full-year guidance of 15–16% growth. EBITDA of ₹56 Cr in H1 (21% margin) aligns the 21% target management raised in the prior call, a claim the company delivered on. But the profit story is split. Mature hospitals — ILS Howrah (+25% H1), ILS Dum Dum (+12% H1), ILS Salt Lake — are executing well, with consolidated occupancy now at 50.3%, up 290 basis points YoY. Excluding Raipur, mature-network occupancy reached 59.8%, indicating pricing and mix are both working. However, Raipur's ₹6.5 Cr H1 loss (₹9 Cr Q2 deterioration) masks that underlying strength. Management guided Raipur to breakeven in Q3 FY27; it now expects breakeven only in Q1 FY28 — a two-quarter miss.
The claims: what holds up, what doesn't
EBITDA margin expanded 150 bps to 21.5% in Q2
₹29.8 Cr EBITDA / ₹135.6 Cr revenue = 22% margin; prior year Q2 ~20%; expansion is 150+ bps YoY
Supported
PAT margin expanded 230 bps to 11.1%
₹15.4 Cr PAT / ₹135.6 Cr revenue = 11.4%; prior Q2 ~8.8%; expansion ~260 bps
Supported
Network occupancy improved 260 bps to 50.3% YoY
50.3% vs 47.4% prior Q2 = 290 bps improvement, not 260
Supported (understated)
Raipur on track to breakeven in Q1 FY28
Originally guided Q3 FY27; now Q1 FY28. Q2 losses ₹9 Cr, deteriorating trajectory from Q1 ₹-2.8 Cr
Contradicted (guidance miss)
ILS Howrah +25% H1 growth; Dum Dum double-digit
Verified; Howrah 45.8% occupancy at +25%, Dum Dum at 68% with +12% growth
Supported
Occupancy trajectory expects 25–30% exit occupancy at Raipur by Q4 FY27
Currently ~30%; suggests marginal progress Q2 to Q4. Competitive pressure (Artemis entry) and talent attrition cited
Supported (but slow ramp)
What changed on this call
Raipur breakeven timeline slipped Q3 FY27 → Q1 FY28 (2-quarter miss)
FY27 EBITDA margin guidance maintained at 21% (hit at 21.5% Q2, 21% H1)
Jamshedpur 155-bed commissioning March–April 2027; expected ₹10 Cr EBITDA loss in FY28
International patient recovery described as 'slow'; below prior run-rate from Bangladesh
FY27 revenue growth guidance 15–16% maintained; H1 at 15.8% on track
The bull-bear ledger
Organic growth strong: 14% revenue, 45% reported PAT; mature hospitals accelerating (Howrah +25%)
EBITDA margin expanded 150 bps to 21.5%; guided to 21%, hit and slightly exceeded
Network occupancy up 290 bps to 50.3%; mature hospitals ex-Raipur at 59.8% — productivity gains real
Raipur breakeven slipped 2 quarters; ₹9 Cr Q2 loss shows deteriorating ramp trajectory
Jamshedpur adds ₹10 Cr annual losses in FY28; cumulative drag ₹20+ Cr through FY28 from two hospitals
Mature hospital occupancy ceiling apparent: Salt Lake 68%, Dum Dum 74%; management admits 80%+ is 'very difficult'
International patient recovery slow; competitive entry at Raipur (Artemis) and talent attrition cited
FY27 debt ₹35 Cr, cash ₹45 Cr; balance sheet capacity for expansion, but leverage will rise
Risks, ranked by urgency for a holder
Raipur execution: occupancy at ~30%, competitive entry (Artemis), talent attrition
HighBreakeven slipped Q3→Q1 FY28. ₹9 Cr Q2 loss masks organic profitability. If occupancy stalls or losses extend beyond Q1 FY28, ROE/ROCE targets (25% target) become unachievable near-term.
Mature hospital occupancy ceiling: 70% max realistic per management
HighSalt Lake 68%, Dum Dum 74% — constrained by bed turnover/downtime. Limits organic leverage. Brownfield bed additions at Agartala/Raipur delayed pending occupancy optimization.
Jamshedpur greenfield losses: ₹10 Cr EBITDA loss expected FY28
Medium155 beds, March–April 2027 commissioning. New market execution risk, consultant retention, ramp-up timeline. Will pressure consolidated ROE through FY28.
International patient recovery stalled: Bangladesh inflow 'slow recovery,' below prior run-rate
MediumVisa process changes impacting patient movement. If recovery remains slow, occupancy upside at specialty units (cardiology, oncology) is constrained.
Supreme Court trade margin ruling (Nov 2026): impact TBD
MediumEssential medicines cap under review. If applied broadly, consumable margins compress. Management can adjust service pricing, but uncertainty remains.
Competitive intensity in Tier 2 markets rising
LowArtemis at Raipur already forced talent response. New entrants in Eastern India markets could pressure pricing/occupancy ramp at future locations.
How the street is positioned
The stock trades at ₹143.81, down 34.6% from its all-time high of ₹219.9 but up 25% off the 52-week low of ₹115. It sits above its 20-day SMA (₹138.69) and 200-day SMA (₹142.87), but below the 50-day SMA (₹148.08), suggesting consolidation and neutral momentum. RSI of 52.1 confirms neither overbought nor oversold conditions. Volume has been increasing, indicating renewed interest. Institutional ownership shows FII at 3.00% (down 0.03pp QoQ) and DII at 7.10% (up 0.16pp), a slight trim by foreign investors balanced by domestic nibbling. Promoter holding remains stable at 65.57%. The drawdown from ATH reflects the market repricing the stock for execution risk (Raipur, Jamshedpur) and the absence of a near-term profitability step-change. The recent uptick from the low, combined with stabilization above key moving averages, suggests the market is cautiously absorbing the guidance miss (Raipur breakeven) as a one-time recalibration rather than a red flag on the long-term thesis.
The debate
What to watch next
1 · Raipur occupancy ramp (Q3–Q4 FY27)
Currently ~30%; guided to 25–30% exit by Q4. If occupancy stays flat or deteriorates further, Q1 FY28 breakeven is at risk. Monthly losses should trend down visibly from ₹9 Cr (Q2) to ₹3–4 Cr or less (Q4) if on track. Watch the trend, not one quarter.
2 · Mature hospital momentum (H2 FY27)
Organic growth is the bull. If Howrah, Dum Dum, Salt Lake, Agartala can sustain double-digit growth and occupancy, consolidated PAT ex-Raipur will be visible. H2 typically slower (seasonal), but any contraction vs. H1 (15.8% growth) flags demand risk or pricing pressure.
3 · Jamshedpur commissioning and FY28 guidance (Mar–Apr 2027, guidance on next call)
Launch in late Q4 FY27. Management will guide on FY28 margins and occupancy. If Jamshedpur ramp is credible (path to breakeven Q2/Q3 FY28) and mature hospitals sustain 15%+ organic growth, the ₹20 Cr two-hospital drag is absorbed. If FY28 margins disappoint or second hospital misses timeline, ROE/ROCE thesis fractures.
The number to track from here
Consolidated PAT ex-Raipur losses. Organic profitability is solid at ~60% YoY growth in H1. Hold the stock if mature hospitals sustain 15%+ growth and Raipur losses trend down to breakeven by Q1 FY28. If either falters — if mature hospital growth drops below 12%, or if Raipur Q3 losses exceed ₹7 Cr — reassess. The ₹143.81 price is fair value if execution holds; at ₹135 it offers 5% downside before the next catalyst (Raipur breakeven or Jamshedpur launch).
GPT Healthcare is not broken, but it is restructuring. Strong organic growth and margin targets are being met, but the cost of Eastern expansion is now live and material. The stock has repriced that risk fairly — down 35% from ATH, it is no longer pricing in a smooth ramp. The question for the next two quarters is whether Raipur can recover and Jamshedpur can launch without further disappointments. Organic momentum exists; execution risk is real. Watch H2 earnings for confirmation.
Informational and educational content only. Not investment advice.